Zenapax

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Newly Diagnosed With Type 1 Diabetes

Conditions

Newly Diagnosed With Type 1 Diabetes

Trial Timeline

Jul 1, 2000 → Feb 23, 2007

NCT ID

NCT00198146

About Zenapax

Zenapax is a phase 2 stage product being developed by Roche for Newly Diagnosed With Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00198146. Target conditions include Newly Diagnosed With Type 1 Diabetes.

What happened to similar drugs?

0 of 5 similar drugs in Newly Diagnosed With Type 1 Diabetes were approved

Approved (0) Terminated (1) Active (4)

🔄Olaparib 300mg tabletsAstraZenecaPhase 3

🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3

❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00198146	Phase 2	Completed	Jul 1, 2000	Feb 23, 2007	Newly Diagnosed With Type 1 Diabetes

Competing Products

18 competing products in Newly Diagnosed With Type 1 Diabetes

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	32
Gliadel Wafer + Temozolomide	Eisai	Phase 2	31
Olaparib 300mg tablets	AstraZeneca	Phase 3	44
Pembrolizumab	Merck	Phase 2	39
Drug (including placebo)	Merck	Phase 1	21
Cilengitide	Merck	Phase 2	31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoB	Novartis	Phase 1	33
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo	Novartis	Phase 2	35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine	Roche	Phase 1	33
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone	Pfizer	Phase 3	47
Elranatamab + Daratumumab + Lenalidomide	Pfizer	Phase 2	42
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 3	47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral	Sanofi	Phase 2	39
Mebendazole	Brain Biotech	Phase 1	19
Balstilimab + Botensilimab + Liposomal Doxorubicin	Agenus	Phase 2	32
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC	Brain Biotech	Phase 1	19